• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay.

作者信息

Aaltonen L, Allonen H, Iisalo E, Juhakoski A, Kleimola T, Sellman R

出版信息

Acta Pharmacol Toxicol (Copenh). 1984 Aug;55(2):100-3. doi: 10.1111/j.1600-0773.1984.tb01969.x.

DOI:10.1111/j.1600-0773.1984.tb01969.x
PMID:6496110
Abstract

The antimuscarinic activity of oxybutynin was measured as oxybutynin equivalents by a radioreceptor assay (RRA). The activity was studied in plasma samples of five volunteers after a single oral dose (10 mg) or after a single intravenous dose (28 micrograms/kg) of oxybutynin hydrochloride. The results were compared to the concentrations of the drug measured by gas liquid chromatography (GLC). Following oral administration, the maximum concentration measured by RRA was significantly higher (706 nmol/l) than that by GLC (38 nmol/l). In contrast, equal concentrations were measured after intravenous administration by both methods. Metabolites with antimuscarinic activity are possibly formed through first-pass metabolism after orally administered oxybutynin. The total antimuscarinic activity of oxybutynin and its metabolites are measured by RRA, but only the parent drug by GLC.

摘要

相似文献

1
Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay.
Acta Pharmacol Toxicol (Copenh). 1984 Aug;55(2):100-3. doi: 10.1111/j.1600-0773.1984.tb01969.x.
2
New insights in the metabolism of oxybutynin: evidence of N-oxidation of propargylamine moiety and rearrangement to enaminoketone.奥昔布宁代谢的新见解:炔丙胺部分N-氧化及重排为烯胺酮的证据。
Xenobiotica. 2018 May;48(5):478-487. doi: 10.1080/00498254.2017.1342288. Epub 2017 Jul 6.
3
Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.新型抗毒蕈碱药物琥珀酸索利那新经口给药后在小鼠体内的毒蕈碱受体结合、血浆浓度及唾液分泌抑制情况
Br J Pharmacol. 2005 May;145(2):219-27. doi: 10.1038/sj.bjp.0706184.
4
The pharmacokinetics of oxybutynin in man.奥昔布宁在人体中的药代动力学。
Eur J Clin Pharmacol. 1988;35(5):515-20. doi: 10.1007/BF00558247.
5
Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.血浆中奥昔布宁及其N-去乙基代谢物的测定及其在年轻、老年和体弱老年志愿者药代动力学研究中的应用。
Xenobiotica. 1992 Jul;22(7):859-69. doi: 10.3109/00498259209053145.
6
Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.健康成年人膀胱内与口服奥昔布宁的药代动力学:一项开放标签、随机、前瞻性临床研究的结果。
J Urol. 2013 Nov;190(5):1791-7. doi: 10.1016/j.juro.2013.05.011. Epub 2013 May 10.
7
Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.索利那新与奥昔布宁在毒蕈碱受体敲除小鼠膀胱和下颌下腺中毒蕈碱受体选择性的比较。
Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13.
8
Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite.
Eur J Clin Pharmacol. 1997;52(5):403-6. doi: 10.1007/s002280050309.
9
Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride.渗透泵控释给药对氯奥昔布宁药代动力学和药效学的影响。
Br J Clin Pharmacol. 2001 Oct;52(4):409-17. doi: 10.1046/j.0306-5251.2001.01463.x.
10
The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids.奥昔布宁的药代动力学不受性别和避孕类固醇的影响。
Eur J Clin Pharmacol. 1998 Jan;53(5):351-4. doi: 10.1007/s002280050392.

引用本文的文献

1
Clinical pharmacokinetics of drugs used to treat urge incontinence.用于治疗急迫性尿失禁药物的临床药代动力学
Clin Pharmacokinet. 2003;42(14):1243-85. doi: 10.2165/00003088-200342140-00004.
2
Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.
Drugs Aging. 1995 Mar;6(3):243-62. doi: 10.2165/00002512-199506030-00007.
3
The pharmacokinetics of oxybutynin in man.奥昔布宁在人体中的药代动力学。
Eur J Clin Pharmacol. 1988;35(5):515-20. doi: 10.1007/BF00558247.